NASDAQ:DSCI Derma Sciences (DSCI) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free DSCI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$7.00▼$7.0050-Day Range N/A52-Week Range$2.92▼$7.05VolumeN/AAverage Volume719,592 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Derma Sciences alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Derma Sciences Stock (NASDAQ:DSCI)Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.Read More Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. DSCI Stock News HeadlinesApril 12, 2024 | msn.comSuccessful murine model of dermatomyositis reveals underlying immune system involvementFebruary 22, 2024 | msn.comDecoding dermatomyositis: All you need to knowMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).January 17, 2024 | msn.comAttain your skincare resolutions with these top dermatologists in 2024October 25, 2023 | msn.comDermatologists To Look Up to This Festive SeasonAugust 30, 2023 | forbes.comIndia's Cyber Security Startups Are Gaining Traction, Thanks To DemonetizationMay 2, 2023 | news.yahoo.comLooking to 'change history,' Japan's Derma Sotogake, Continuar work toward Kentucky DerbyFebruary 13, 2023 | nypost.comThe 7 is best derma rollers for microneedling, with dermatologists’ tipsMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).August 24, 2022 | finance.yahoo.comDermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV CongressAugust 2, 2022 | finance.yahoo.comDermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy InjectionsJuly 27, 2022 | seekingalpha.comDerma Sciences Inc. (DSCI) CEO Jan De Witte on Q2 2022 Results - Earnings Call TranscriptJuly 27, 2022 | apnews.comCORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation TestingSee More Headlines Receive DSCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Derma Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2016Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:DSCI CUSIP24982750 CIK892160 Webwww.dermasciences.com Phone+1-609-5144744FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report DSCI Stock Analysis - Frequently Asked Questions How were Derma Sciences' earnings last quarter? Derma Sciences Inc (NASDAQ:DSCI) issued its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.16. The medical instruments supplier earned $22.20 million during the quarter, compared to analysts' expectations of $22.40 million. What other stocks do shareholders of Derma Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Derma Sciences investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN), Allena Pharmaceuticals (ALNA), Antares Pharma (ATRS), Fate Therapeutics (FATE), Genetic Technologies (GENE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Molecular Templates (MTEM). This page (NASDAQ:DSCI) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe asset beating inflation by 4xColonial MetalsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressUrgent Nvidia WarningAltimetryRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Derma Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
